Insmed, Inc. (NASDAQ:INSM - Get Free Report)'s stock price reached a new 52-week high during trading on Monday after Guggenheim raised their price target on the stock from $125.00 to $172.00. Guggenheim currently has a buy rating on the stock. Insmed traded as high as $146.91 and last traded at $145.86, with a volume of 288114 shares changing hands. The stock had previously closed at $145.10.
Several other research analysts have also weighed in on INSM. Stifel Nicolaus increased their price objective on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Leerink Partners increased their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Bank of America increased their price objective on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Royal Bank Of Canada raised their price target on Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Morgan Stanley raised their price target on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average target price of $139.86.
Get Our Latest Research Report on Insmed
Insider Transactions at Insmed
In related news, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the transaction, the insider directly owned 54,902 shares in the company, valued at approximately $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $129.50, for a total value of $1,295,000.00. Following the completion of the transaction, the director owned 274,516 shares of the company's stock, valued at approximately $35,549,822. This trade represents a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 378,382 shares of company stock valued at $40,169,038 in the last 90 days. Insiders own 3.00% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after purchasing an additional 49,149 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Insmed by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after purchasing an additional 219,131 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Insmed by 109.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership raised its stake in Insmed by 3.0% in the second quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company's stock valued at $333,555,000 after buying an additional 97,073 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Insmed by 2.5% in the first quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company's stock valued at $184,890,000 after buying an additional 59,952 shares in the last quarter.
Insmed Stock Performance
The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The company has a market capitalization of $30.85 billion, a price-to-earnings ratio of -25.56 and a beta of 0.97. The stock has a 50 day simple moving average of $119.40 and a two-hundred day simple moving average of $91.91.
Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the prior year, the business earned ($1.94) earnings per share. The firm's quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Articles
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.